IMPROVED THERAPEUTIC CONTROL OF HETERODIMERIC AND SINGLE CHAIN FORMS OF INTERLEUKIN-12
摘要
The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL- 12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.
申请公布号
WO2016048903(A1)
申请公布日期
2016.03.31
申请号
WO2015US51246
申请日期
2015.09.21
申请人
INTREXON CORPORATION;REED, CHARLES, C.;FROST, GREGORY, IAN;SOPCZYNSKI, JOAN, MAZZARELLI;ZHANG, CHI
发明人
REED, CHARLES, C.;FROST, GREGORY, IAN;SOPCZYNSKI, JOAN, MAZZARELLI;ZHANG, CHI